Terms: = Endocrine gland cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Prognosis
61 results:
1. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
2. A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Xu Y; Wang Y
J Ovarian Res; 2023 Sep; 16(1):196. PubMed ID: 37730669
[TBL] [Abstract] [Full Text] [Related]
3.
Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
[TBL] [Abstract] [Full Text] [Related]
4. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C
Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500
[TBL] [Abstract] [Full Text] [Related]
5. Papillary thyroid carcinoma with aggressive fused follicular and solid growth pattern: A unique histological subtype with high-grade malignancy?
Murata SI; Matsuzaki I; Kishimoto M; Katsuki N; Onishi T; Hirokawa M; Kojima F
Pathol Int; 2023 May; 73(5):207-211. PubMed ID: 37042564
[TBL] [Abstract] [Full Text] [Related]
6. Significance of oncocytic features in poorly differentiated thyroid carcinoma - a bi-institutional experience.
Xu B; Lubin DJ; Dogan S; Ghossein RA; Viswanathan K
Virchows Arch; 2023 Mar; 482(3):479-491. PubMed ID: 36346459
[TBL] [Abstract] [Full Text] [Related]
7. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract] [Full Text] [Related]
8. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
[TBL] [Abstract] [Full Text] [Related]
9. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract] [Full Text] [Related]
10. Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
[TBL] [Abstract] [Full Text] [Related]
11. N6-Methyladenosine-Related RNA Signature Predicting the prognosis of Ovarian cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract] [Full Text] [Related]
12. [The possibility of using freely circulating DNA blood plasma in preoperative diagnosis of thyroid tumors].
Kachko VA; Vanushko VE; Platonova NM; Abrosimov AY; Tely Sheva EN; Snigireva GP
Probl Endokrinol (Mosk); 2020 Jun; 65(6):400-407. PubMed ID: 33351322
[TBL] [Abstract] [Full Text] [Related]
13. The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract] [Full Text] [Related]
14. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
Samà MT; Grosso E; Mele C; Laurora S; Monzeglio O; Marzullo P; Boldorini R; Aluffi Valletti P; Aimaretti G; Scatolini M; Pagano L
Endocrine; 2021 Jan; 71(1):149-157. PubMed ID: 32621051
[TBL] [Abstract] [Full Text] [Related]
15. Risk Stratification Using a Novel Genetic Classifier Including
Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
[No Abstract] [Full Text] [Related]
16. Cold Shock Domain Containing E1 (CSDE1) Protein is Overexpressed and Can be Targeted to Inhibit Invasiveness in Pancreatic cancer Cells.
Liu H; Li X; Dun MD; Faulkner S; Jiang CC; Hondermarck H
Proteomics; 2020 May; 20(10):e1900331. PubMed ID: 32170829
[TBL] [Abstract] [Full Text] [Related]
17. Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid cancer.
Masoodi T; Siraj AK; Siraj S; Azam S; Qadri Z; Albalawy WN; Parvathareddy SK; Al-Sobhi SS; Al-Dayel F; Alkuraya FS; Al-Kuraya KS
Thyroid; 2020 Jan; 30(1):42-56. PubMed ID: 31668133
[No Abstract] [Full Text] [Related]
18. miR-29a Is Repressed by MYC in Pancreatic cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.
Dey S; Kwon JJ; Liu S; Hodge GA; Taleb S; Zimmers TA; Wan J; Kota J
Mol Cancer Res; 2020 Feb; 18(2):311-323. PubMed ID: 31662451
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
[TBL] [Abstract] [Full Text] [Related]
20. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.
Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
[No Abstract] [Full Text] [Related]
[Next]
